Summary
Carvedilol, a β-blocking drug with vasodilator activity, has been used in 4 studies in 107 elderly patients with essential hypertension and has reduced blood pressure effectively. In the first study the pharmacokinetics and clinical response were compared between 21 patients > 65 years of age and 8 patients aged 35–50 years). The peak blood levels, time to maximal concentration, area under the curve, half-life and trough level of the drug with chronic administration did not differ. The clinical responses to the drug were similar, with a greater fall in systolic blood pressure in the older group. However the initial systolic blood pressure in the older group was higher. Carvedilol was compared with metoprolol, pindolol and nitrendipine in elderly patients. The responses to carvedilol were at least equal to those obtained with the other drugs. Control was achieved in the three studies with once-daily therapy. There was no significant postural hypotensive effect. A feature of all studies was the large number of patients who responded to carvedilol. The side-effect profile of the drug was acceptable; headache and dizziness were more common than with placebo or the comparison drugs and were frequently associated. There were no adverse biochemical effects and the lipid profile was not altered. Carvedilol is an effective antihypertensive drug that lowers blood pressure equally well in the young and the old.
Similar content being viewed by others
References
Abshagen U (1987) A new molecule with vasodilating and β-adrenoreceptor blocking properties. J Cardiovasc Pharmacol 10 [Suppl 11]: 23–32
Schnurr E, Widmann L, Glocke M (1987) Efficacy and safety of carvedilol in the treatment of hypertension. J Cardiovasc Pharmacol 10 [Suppl 11]: 101–107
Heber ME, Brigden GS, Caruana MP, Lahiri A, Raftery EB (1987) Carvedilol for systemic hypertension. J Cardiovasc Pharmacol 10 [Suppl 11]: 113–118
Eggertsen R, Sivertsson R, Andren L, Hansson L (1984) Haemodynamic effects of cavedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens 2: 529–534
Ogihara T, Ikeda M, Goto Y, Yoshinaga K, Kumahara Y, Iimura O, Ishii M, Murakami E, Takeda T, Kokubu T, Arakawa K (1987) The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. J Cardiovasc Pharmacol 10 [Suppl 11]: 108–112
Bourliere F, Vallery-Masson J (1985) Epidemiology and ecology of aging. In: Brocklehurst J (ed) Textbook of geriatric medicine and gerontology. Churchill Livingstone, Edinburgh, pp 3–28
Morgan TO, Snowden R, Butcher L (1987) Effect of carvedilol and metoprolol on blood pressure, blood flow and vascular resistance. J Cardiovasc Pharmacol 10 [Suppl 11]: 124–129
Staiger Ch, Steger W, Widmann L, Ehmer B, Holtbrugge W (1989) Double-blind, controlled clinical trial to evaluate the antihypertensive effect of carvedilol in elderly patients with mild to moderate hypertension. Drugs (in press)
Reiff K (1985) Quantitative determination of BM 14.242 and BM 14.190 (carvedilol) in body fluids. Documentation. Boehringer Mannheim, Federal Republic of Germany
Louis WJ, McNeil JJ, Workman BS, Drummer OH, Conway EL (1987) A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 10 [Suppl 11]: 89–93
Neugebauer G, Akpan W, Mollendorff EV, Neubert P, Reiff K (1987) Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 10 [Suppl 11]: 85–88
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morgan, T.O., Anderson, A., Cripps, J. et al. The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol 38 (Suppl 2), S129–S133 (1990). https://doi.org/10.1007/BF01409482
Issue Date:
DOI: https://doi.org/10.1007/BF01409482